

# Interleukin-17A (IL-17A): the silent amplifier of COVID-19

Francesco Maione<sup>1</sup>, Gian Casillo<sup>2</sup>, Federica Raucci<sup>1</sup>, and Mariarosaria Bucci<sup>1</sup>

<sup>1</sup>University of Naples Federico II Department of Pharmacy

<sup>2</sup>University of Naples Federico II School of Medicine and Surgery

April 12, 2021

## Abstract

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated levels of interleukin-17A (IL-17A) and disease severity and progression. Considering that per se IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, this cytokine can represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.

## Hosted file

Maione F et al, Manuscript.pdf available at <https://authorea.com/users/363869/articles/517760-interleukin-17a-il-17a-the-silent-amplifier-of-covid-19>



